madman
Super Moderator
* Intracavernous injections are highly effective and safe. The implementation of standardized formulations and dosing protocols is essential to optimize outcomes, minimize adverse effects, and reduce therapy discontinuation.
RESULTS AND DISCUSSION
As previously mentioned, ICI therapy may be administered as monotherapy or combination therapy (bimix, trimix, or quadrimix) to promote erection. Each pharmacological compound has distinct mechanisms of action and potential adverse effects, and combining them enables a multi-mechanistic approach, enhancing synergistic efficacy while allowing lower individual drug concentrations. This strategy may improve tolerability and reduce the incidence of dose-dependent adverse events associated with higher single-agent doses (9). The four vasoactive agents for ICI combinations are prostaglandine, papaverine, phentolamine, and atropine.
AGENTS AND SOLUTIONS
Prostaglandin E1 - (PGE1)
Papaverine
Phentolamine
Atropin
Combination
Adverse Effects
The majority of side effects of the intracavernous injection are related to the puncture site or local complications. Otherwise, the rates of side effects are conflicting in the literature and range from 5% to 94% (24–26).
About starting the treatment for erectile dysfunction
The Patient Selection
Contraindications
Injection training
Choosing a vasoagent and starting dose
Dose adjustment
Management of adverse events and complications
Practical Considerations
Follow-up Protocol
CONCLUSIONS
Intracavernous injections are highly effective and safe. The implementation of standardized formulations and dosing protocols is essential to optimize outcomes, minimize adverse effects, and reduce therapy discontinuation. ICI should be considered the second-line therapy for ED after failure of PDE5i and should be considered before the indication of penile prosthesis surgery.
RESULTS AND DISCUSSION
As previously mentioned, ICI therapy may be administered as monotherapy or combination therapy (bimix, trimix, or quadrimix) to promote erection. Each pharmacological compound has distinct mechanisms of action and potential adverse effects, and combining them enables a multi-mechanistic approach, enhancing synergistic efficacy while allowing lower individual drug concentrations. This strategy may improve tolerability and reduce the incidence of dose-dependent adverse events associated with higher single-agent doses (9). The four vasoactive agents for ICI combinations are prostaglandine, papaverine, phentolamine, and atropine.
AGENTS AND SOLUTIONS
Prostaglandin E1 - (PGE1)
Papaverine
Phentolamine
Atropin
Combination
Adverse Effects
The majority of side effects of the intracavernous injection are related to the puncture site or local complications. Otherwise, the rates of side effects are conflicting in the literature and range from 5% to 94% (24–26).
About starting the treatment for erectile dysfunction
The Patient Selection
Contraindications
Injection training
Choosing a vasoagent and starting dose
Dose adjustment
Management of adverse events and complications
Practical Considerations
Follow-up Protocol
CONCLUSIONS
Intracavernous injections are highly effective and safe. The implementation of standardized formulations and dosing protocols is essential to optimize outcomes, minimize adverse effects, and reduce therapy discontinuation. ICI should be considered the second-line therapy for ED after failure of PDE5i and should be considered before the indication of penile prosthesis surgery.
